BRIUMVI ® (ublituximab-xiiy)
WEBBRIUMVI ® (ublituximab-xiiy) is available for people with relapsing multiple sclerosis (RMS), the only B-cell therapy for RMS that is administered in 1 hour, twice per year.
BRIUMVIdirect Home
WEBWelcome to BRIUMVIdirect. Thank you for choosing to purchase BRIUMVI (ublituximab-xiiy) through our direct ordering program, BRIUMVIdirect. Ordering through BRIUMVIdirect is quick and easy, allowing for a seamless customer experience.
6 Briumvi Side Effects and How to Manage Them - GoodRx
WEB5 days ago · Common Briumvi (ublituximab) side effects include mild infusion reactions and infections. You may also experience pain in your arms or legs, insomnia, or fatigue. While rare, severe infusion reactions (such as anaphylaxis) and serious infections are possible.
Briumvi: Side Effects, Cost, Dosage, Uses, and More - Healthline
WEBSep 10, 2024 · Learn about side effects, cost, dosage, and more for Briumvi. It's a prescription drug used to treat certain types of multiple sclerosis (MS) in adults.
Briumvi: Uses, Dosage, Side Effects & Warnings - Drugs.com
WEBMar 11, 2024 · Briumvi (ublituximab) is used for the treatment of relapsing forms of multiple sclerosis (MS). Includes Briumvi side effects, interactions and indications.
Managing Multiple Sclerosis With Briumvi: What You Need to …
WEBAug 27, 2024 · Briumvi is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary...
Briumvi for Multiple Sclerosis - HealthCentral
WEBDec 12, 2023 · Briumvi (ublituximab-xiiy) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting...
Briumvi - MS Living Well
WEBBriumvi (ublituximab) is an antibody treatment given in the vein that removes B cells in the body. The first dose is 150 mg given over 4 hours, followed by 450 mg dose over 1 hour 2 weeks later. Follow-up doses are 450 mg over 1 hour every 6 months.
Briumvi (ublituximab-xiiy) | MultipleSclerosis.net
WEBBriumvi ® (ublituximab-xiiy) is approved to treat adults with relapsing forms of multiple sclerosis (MS). These include relapsing-remitting MS, active secondary progressive MS, and clinically isolated syndrome. 1,2. In people with these types of MS, symptoms flare for at least 24 hours. This is called a relapse.
BRIUMVI ® (ublituximab-xiiy) HCP
WEBBRIUMVI is a CD20-directed cytolytic antibody that is designed for efficient B-cell depletion. 1,2. Glycoengineered design. See BRIUMVI Design. Convenient administration. The only anti-CD20 therapy that is administered as a 1-hour infusion, twice per year. 1,3,a. 95% of all BRIUMVI infusions were delivered without interruption.